LEADER 04403nam 2201081z- 450 001 9910566479403321 005 20220506 035 $a(CKB)5680000000037586 035 $a(oapen)https://directory.doabooks.org/handle/20.500.12854/81230 035 $a(oapen)doab81230 035 $a(EXLCZ)995680000000037586 100 $a20202205d2022 |y 0 101 0 $aeng 135 $aurmn|---annan 181 $ctxt$2rdacontent 182 $cc$2rdamedia 183 $acr$2rdacarrier 200 00$aRare Respiratory Diseases: A Personal and a Public Health Problem 210 $aBasel$cMDPI - Multidisciplinary Digital Publishing Institute$d2022 215 $a1 online resource (242 p.) 311 08$a3-0365-3669-8 311 08$a3-0365-3670-1 330 $aDear Colleagues, A rare disease, also known as an orphan disease, is any disease that affects a small percentage of the population. Although definitions vary from continent to continent, according to the European Union, rare diseases are those with a prevalence of less than 1 in 2000 people. Rare diseases are, in general, chronic, debilitating diseases, which in many cases threaten patients' lives. It is estimated that 1-2 million people in the European Union are affected by a rare respiratory disease, which is a public health problem. Due to the low prevalence and severity of many of these diseases, whose symptoms often initially manifest in childhood, combined efforts are needed to improve our knowledge of the pathophysiology of these diseases that will lead to the development of new, more effective treatments. Therefore, since rare respiratory diseases represent an important field in medicine, we propose this Special Issue to promote the dissemination of the latest advances in basic and clinical research in these diseases. Prof. Dr. Francisco Dasi? Guest Editor 517 $aRare Respiratory Diseases 606 $aMedicine and Nursing$2bicssc 606 $aPharmacology$2bicssc 610 $aactive lifestyle 610 $aALI culture 610 $aalpha-1 antitrypsin deficiency 610 $aAlpha-1 antitrypsin deficiency 610 $aalpha-1-antitrypsin deficit 610 $aalpha1 antitrypsin deficiency 610 $aalpha1-antitrypsin deficiency 610 $aantibody 610 $aantioxidant therapies 610 $aasthma 610 $aaugmentation therapy 610 $abio-resource 610 $abronchiectasis 610 $achronic obstructive pulmonary disease 610 $acilia 610 $aclinical presentation 610 $acystic fibrosis 610 $adiagnostics 610 $aemphysema 610 $aendoplasmic reticulum stress 610 $aexhaled breath condensate 610 $aflow cytometry 610 $agamma-glutamyl transpeptidase 610 $agene therapy 610 $aglutamate-oxaloacetate transaminase 610 $aglutamate-pyruvate transaminase 610 $aidiopathic pulmonary fibrosis 610 $aimmunofluorescence 610 $ainfection control measure 610 $alaterality defect 610 $aliver disease 610 $amiRNA expression 610 $aMycobacterium avium 610 $aMycobacterium intracellulare 610 $an/a 610 $anasal epithelium 610 $aneonatal respiratory distress 610 $anodular bronchiectasis 610 $anon-tuberculous mycobacteria 610 $aorphan diseases 610 $aoxidative stress 610 $aPCD 610 $aprimary ciliary dyskinesia 610 $aprimary nasal epithelium 610 $apulmonary aspergillosis 610 $apulmonary exacerbation 610 $arare diseases 610 $arare pulmonary disease 610 $arare respiratory diseases 610 $areactive oxygen species 610 $areference centres 610 $areplacement therapy 610 $aresilience 610 $aself-quarantine 610 $aseverity 610 $asputum 610 $astandard diagnosis 610 $astress levels 610 $atransient elastography 615 7$aMedicine and Nursing 615 7$aPharmacology 700 $aDasi?$b Francisco$4edt$01303404 702 $aDasi?$b Francisco$4oth 906 $aBOOK 912 $a9910566479403321 996 $aRare Respiratory Diseases: A Personal and a Public Health Problem$93027003 997 $aUNINA